Companies: 10,795·Total market cap: $144.5T
Inventiva S.A.

Inventiva S.A.

IVEVFOTCHealthcare● Active
$4.00
$-1.33(-24.95%)
Market Cap$556245172
P/E Ratio—
52W High$5.75
52W Low$2.28
Cash on HandFinancialsRevenue

Inventiva S.A. (IVEVF) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

IVEVF · cash on hand · updated Dec 31, 2025

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$230.9M▲ +139.1% vs prior year
FY · as of Dec 31, 2025 · Reported in EUR
Cash & Cash Equiv. (CCE)
$99.3M
cashAndCashEquivalents
Short-Term Investments
$131.6M
shortTermInvestments
YoY Change vs Prior Year
+139.1%
vs prior fiscal year
Latest Quarter
$230.9M
Q4 2025
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in EUR

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash & ST Investments$230.9MCash on Hand
Total Debt$59.9MTotal Debt
Net Cash / Net Debt+$171.0MNet Cash Position
Cash vs Debt Ratio
Cash 79%Debt 21%

Inventiva S.A. has a net cash position of $171.0M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$230.9M − $59.9M = +$171.0M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
IVEVF annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2025Latest$230.9M+139.1%
Dec 31, 2024$96.6M+257.8%
Dec 31, 2023$27.0M-69.3%
Dec 31, 2022$87.8M-8.0%
Dec 31, 2021$95.4M-15.6%
IVEVF cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.6%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Inventiva S.A.
Inventiva S.A.YOU
IVEVF
$230.9M41.5%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Inventiva S.A. (IVEVF) cash on hand as of December 31, 2025 is $230.9M, comprising $99.3M in cash and cash equivalents (CCE) plus $131.6M in short-term investments — reported as Inventiva S.A. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Inventiva S.A. cash reserves or cash position.

Inventiva S.A. annual cash on hand history shows increased +139.1% in 2025: increased +139.1% in 2025. Inventiva S.A. cash reserves in 2025 reflect the company's capital allocation strategy.

Inventiva S.A. carries total debt of $59.9M against cash of $230.9M, resulting in a net cash position of +$171.0M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

IVEVF cash on hand · 5 questions

As of December 31, 2025, Inventiva S.A. (IVEVF) has $230,870,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $99,312,000 in cash and cash equivalents (CCE) plus $131,558,000 in short-term investments. Latest quarter (December 31, 2025): $230,870,000. Data sourced from the annual 10-K filing via FMP.

IVEVF cash on handIVEVF cash reservesIVEVF cash 2025how much cash does IVEVF have

▸ Source: FMP /balance-sheet-statement · US GAAP · Inventiva S.A. · Inventiva S.A. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025